A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

  • STATUS
    Recruiting
  • End date
    Mar 11, 2022
  • participants needed
    316
  • sponsor
    Helsinn Healthcare SA
Updated on 11 December 2020
Investigator
Edwin De Wit, MD
Primary Contact
MercyOne Waterloo Cancer Center (1.5 mi away) Contact
+72 other location
body mass index
renal function
lung cancer
metastasis
liver metastases
cancer treatment
palliative care
cancer chemotherapy
targeted therapy
metastatic cancer
anorexia
anamorelin
anamorelin hydrochloride
kidney function test
lung carcinoma
secondary malignant neoplasm of liver

Summary

Multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl. Approximately 316 patients with advanced NSCLC with cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once daily (QD) for a total of 24 weeks. Patients will be instructed to take the study drug at least 1 hour before their first meal of the day

Details
Treatment Placebo Oral Tablet, Anamorelin Hydrochloride
Clinical Study IdentifierNCT03743051
SponsorHelsinn Healthcare SA
Last Modified on11 December 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Non-Small Cell Lung Cancer or Cachexia; Cancer?
Do you have any of these conditions: nsclc or Cachexia; Cancer or Non-Small Cell Lung Cancer?
Do you have any of these conditions: Non-Small Cell Lung Cancer or Cachexia; Cancer or nsclc?
Signed written informed consent
Female or male 18 years of age
Documented histologic or cytologic diagnosis of American Joint Committee on Cancer (AJCC) Stage III or IV NSCLC. Stage III patient must have unresectable disease
Body mass index < 20 kg/m2 with involuntary weight loss of >2% within 6 months prior to screening
Ongoing problems with appetite/eating associated with the underlying cancer, as determined by having score of 17 points on the 5-item Anorexia Symptom Scale and 37 points on the 12-item FAACT A/CS
Patient receiving or not receiving systemic anti-cancer treatment at the time of screening are eligible to participate. Systemic anti-cancer treatment includes first, second, third treatment line with chemotherapy/radiation therapy, immunotherapy or targeted therapy
Patient not receiving systemic anti-cancer treatment is eligible if
Not planning to receive anti-cancer treatment and/or at least 14 days must be elapsed from the completion of prior treatment at the day of screening, in case underwent previous cycle OR
Planning to receive anti-cancer treatment within 14 days from randomization and/or at least 14 days must be elapsed from the completion of prior treatment at the day of screening, in case underwent previous cycle OR
Patient on palliative care treatment
ECOG performance status 0,1 or 2 at screening
AST (SGOT) and ALT (SGPT) 3 x ULN or if hepatic metastases are present 5 x ULN
Adequate renal function, defined as creatinine 2 ULN, or calculated creatinine clearance >30 ml/minute
Female patient shall be: a) of non-childbearing potential or b) of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test within 24 hours prior to first dose of investigational product
Notes
Female patient of non-childbearing potential are defined as being in post-menopausal state since at least 1 year; or having documented surgical sterilization or hysterectomy at least 3 months before study participation
Reliable contraceptive measures include implants, injectables, combined oral contraceptives, intrauterine devices, vasectomized partner or complete (long term) sexual abstinence
The patient must be willing and able to comply with the protocol tests and procedures All inclusion criteria will be checked at screening visit (Visit 1)

Exclusion Criteria

Patient with other forms of lung cancer (e.g., small cell, neuroendocrine tumors)
Woman who is pregnant or breast-feeding
Reversible causes of reduced food intake, as determined by the Investigator. These causes may include but are not limited to
NCI CTCAE Grade 3 or 4 oral mucositis
NCI CTCAE Grade 3 or 4 GI disorders [nausea, vomiting, diarrhea, and constipation]
mechanical obstructions making patient unable to eat, or
severe depression
Patient undergoing major surgery (central venous access placement and tumor biopsies are not considered major surgery) within 4 weeks prior to randomization. Patient must be well recovered from acute effects of surgery prior to screening. Patient should not have plans to undergo major surgical procedures during the treatment period
Patient currently taking androgenic compounds (including but not limited to testosterone, testosterone-like agents, oxandrolone, megestrol acetate, corticosteroids, olanzapine, mirtazapine (however, long-term use of mirtazapine for depression for at least four weeks prior to screening is allowed), dronabinol or marijuana (cannabis) or any other prescription medication or off-label products intended to increase appetite or treat unintentional weight loss
Patient with pleural effusion requiring thoracentesis, pericardial effusion requiring drainage, edema or evidence of ascites
Patient with uncontrolled or significant cardiovascular disease, including
History of myocardial infarction within the past 3 months
A-V block of second or third degree (may be eligible if currently have a pacemaker)
Unstable angina
Congestive heart failure within the past 3 months, if defined as NYHA class III-IV
Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, Wolff-Parkinson-White (WPW) syndrome, or torsade de pointes)
Uncontrolled hypertension (blood pressure >150 mm Hg systolic and >95 mm Hg diastolic)
Heart rate < 50 beats per minute on pre-entry electrocardiogram and patient is symptomatic
Patient on drugs that may prolong the PR or QRS interval durations, such as any of the antiarrhythmic medications Class I (Fast sodium (Na) channel blockers)
Patient unable to readily swallow oral tablets
Patient with severe gastrointestinal disease (including esophagitis, gastritis, malabsorption)
Patient with history of gastrectomy
Patient with uncontrolled diabetes mellitus or unmonitored diabetes mellitus
Patient with cachexia caused by other reasons, as determined by the investigator such
as
Severe COPD requiring use of home O2
New York Heart Association (NYHA) class III-IV heart failure
AIDS
Uncontrolled thyroid disease
Patient receiving strong CYP3A4 inhibitors within 14 days of randomization
Patient currently receiving tube feedings or parenteral nutrition (either total or partial)
Current excessive alcohol or illicit drug use
Any condition, including the presence of laboratory abnormalities, which in the Investigator's opinion, places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
Enrollment in a previous study with anamorelin HCl
Patient actively receiving a concurrent investigational agent, or having received an investigational agent within 28 days of Day 1 All exclusion criteria will be checked at screening visit (Visit 1)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet